long intergenic non-protein coding RNA 1347Genealiases: []
Q-omics provides the consensus-scored LINC01347 profile across patient tissues and cancer cell-line models. LINC01347 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, LINC01347 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, LINC01347 RNA expression shows 19,530 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight THCA, and THYM as cancer lineages where LINC01347 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01347 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01347 survival associations across molecular data types. LINC01347 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01347 RNA expression–survival associations across cancer types. High LINC01347 expression shows unfavorable associations in THCA, CESC, BLCA and LGG, but favorable associations in HNSC and PAAD. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify THCA as the clearest survival context for LINC01347 RNA expression.
This table summarizes LINC01347 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01347. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01347 shows lower tumor expression in THCA and higher tumor expression in HNSC, LUSC, CHOL, COAD and LIHC. The THCA box plot shows higher LINC01347 RNA expression in normal versus tumor tissue (log2 FC = −0.208, t-test p < 0.001).
This table shows molecular features associated with LINC01347 in patient tissues and cancer cell lines. In patient samples, LINC01347 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
